Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study

Bill J Wright, Samuel Tideman, George A Diaz, Thomas French, Guilford T Parsons, Ari Robicsek

Summary

Background Research suggests the protection offered by COVID-19 vaccines might wane over time, prompting consideration of booster vaccinations. Data on which vaccines offer the most robust protection over time, and which patients are most vulnerable to attenuating protection, could help inform potential booster programmes. In this study, we used comprehensive hospitalisation data to estimate vaccine effectiveness over time.

Methods In this case-control study, we used data from a large US health-care system to estimate vaccine effectiveness against severe SARS-CoV-2 infection and examined variation based on time since vaccination, vaccine type, and patients’ demographic and clinical characteristics. We compared trends in attenuation of protection across vaccines and used a multivariable model to identify key factors associated with risk for severe breakthrough infection. Patients were considered to have severe COVID-19 if they were admitted to the hospital, had a final coded diagnosis of COVID-19 (according to International Classification of Diseases Tenth Revision code U07.1) or a positive nucleic acid amplification test for symptomatic SARS-CoV-2 during their hospitalisation, and were treated with remdesivir or dexamethasone during hospitalisation.

Findings Between April 1, 2021, and Oct 26, 2021, we observed 9667 admissions for severe COVID-19 (ie, cases). Overall, 1293 (13.4%) of 9667 cases were fully vaccinated at the time of admission, compared with 22308 (57.7%) of 38668 controls, who were admitted to hospital for other reasons. The median time between vaccination and hospital admission among cases was 162 days (IQR 118–198). Overall vaccine effectiveness declined mostly over the course of the summer, from 94.5% (95% CI 91.4–96.5) in April, 2021 (pre-delta), to 84.0% (81.6–86.1) by October, 2021. Notably, vaccine effectiveness declined over time, from 94.0% (95% CI 92.8–95.0) at days 50–100 after vaccination to 80.4% (77.8–82.7) by days 200–250 after vaccination. After 250 days, vaccine effectiveness declines were even more notable. Among those who received the BNT162b2 (Pfizer-BioNTech) vaccine, vaccine effectiveness fell from an initial peak of 94.9% (93.2–96.2) to 74.1% (69.6–77.9) by days 200–250 after vaccination. Protection from the mRNA-1273 (Moderna) and Ad26.COV2 (Janssen) vaccines declined less over time, although the latter offered lower overall protection. Holding other factors constant, the risk of severe breakthrough infection was most strongly associated with age older than 80 years (adjusted odds ratio 1.76, 95% CI 1.43–2.15), vaccine type (Pfizer 1.39, 0.98–1.97; Janssen 14.53, 8.43–25.03; both relative to Moderna), time since vaccination (1.05, 1.03–1.07; per week after week 8 when protection peaks, technically), and comorbidities including organ transplantation (3.44, 95% CI 2.12–5.57), cancer (1.93, 1.60–2.33), and immunodeficiency (1.49, 1.13–1.96).

Interpretation Vaccination remains highly effective against hospitalisation, but vaccine effectiveness declined after 200 days, particularly for older patients or those with specific comorbidities. Additional protection (eg, a booster vaccination) might be warranted for everyone, but especially for these populations. In addition to promoting general vaccine uptake, clinicians and policy makers should consider prioritising booster vaccinations in those most at risk of severe COVID-19.

Funding None.

Copyright © 2022 Published by Elsevier Ltd. All rights reserved.

Introduction Concern about waning COVID-19 vaccine effectiveness has prompted intense public discussion about the need for booster vaccinations, particularly given the rise of the SARS-CoV-2 delta (B.1.617.2) variant. Pre-delta variant studies showed that the vaccines had high effectiveness, which remained largely intact for up to 6 months. Early research on the delta variant suggested only a modest difference in vaccine effectiveness, but subsequent reports suggested protection against delta infection might be somewhat lower than previous variants. A US study found vaccine effectiveness fell from 92% to 80% as delta cases rose, although vaccine effectiveness against hospitalisation remained at 90%. Another study that focused on patients in nursing homes saw vaccine effectiveness decline from 75%
Evidence before this study
Previous studies have used retrospective case-control designs to assess vaccine effectiveness against severe SARS-CoV-2 infection requiring hospitalisation. Results have shown strong overall protection, but some indications that protection might begin to wane as patients approach 6 months post-vaccination. These results have given rise to substantial discussion about the merits of potential booster shots. We searched MEDLINE between March 1, 2020, to Nov 15, 2021, using the terms “covid-19 vaccine studies”, “covid-19 vaccine effectiveness”, and “covid-19 vaccine efficacy”. We considered only publication in English or with English translations.

Added value of this study
We used a case-control design similar to other published studies and found similar overall estimates of vaccine effectiveness. We added three distinct points of additional value. First, we extended existing studies to examine potential attenuation of protection beyond 6 months, finding evidence of significant declines in protection after 200 days post-vaccination for some patients. Second, we examined whether different vaccines differed in terms of waning protection over time, finding that the BNT162b2 (Pfizer-BioNTech) vaccine is particularly susceptible to declines after 200 days, whereas the mRNA-1273 (Moderna) and Ad26.COV2 (Janssen) vaccines are more robust over time, although the Janssen vaccine offers lower overall vaccine effectiveness. Finally, we found that, keeping other factors constant in a multivariable model, the risk of having a severe breakthrough infection was most strongly associated with age older than 80 years, vaccine type, time since vaccination, and specific comorbidities, including cancer, organ transplantation, chronic kidney disease, hypertension, or heart failure.

Implications of all the available evidence
Our results could help with purchasing and prioritising decisions for any potential booster vaccine programme. There are important differences in performance over time by vaccine type, and important differences in the risks of severe breakthrough infection by patient type, which should inform policy, programmatic, and clinical decision making around booster vaccinations.

Methods
Overview and objectives
In this study, we used comprehensive hospital admission data from a large US health-care system (Providence) to analyse vaccine effectiveness against severe COVID-19 over time using a case-control design. To help understand how protection changed over time and inform decisions about potential booster programmes, we examined variation in vaccine effectiveness over time by vaccine type and specified a multivariable model to identify key individual factors that shape the
risk of a vaccinated person having a severe breakthrough COVID-19 infection.

This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, and was approved by the Providence Institutional Review Board (study #2021000504), which authorised a waiver of consent for this retrospective records review.

Data sources and variables
Hospital inpatient encounter records were obtained from electronic medical records covering 42 hospitals in six western US states over a 7-month period (April 1 to Oct 26, 2021). These hospitals are in Alaska, Washington, Oregon, California, Montana, and Texas and serve a catchment of about 6 million individuals. April 1, 2021, was selected as a start date because there were very few earlier COVID-19 hospitalisations of vaccinated patients before this date. Patients younger than 18 years or admitted for elective inpatient care were excluded from the study. Data collected on study patients were admission date, diagnoses, demographics, comorbidities, COVID-19 status (collected at admission for all patients), and vaccination status.

Patients were considered to have severe COVID-19 if they were admitted to the hospital, had a final coded diagnosis of COVID-19 (according to International Classification of Diseases Tenth Revision [ICD-10] code U07.1) or a positive nucleic acid amplification test for symptomatic SARS-CoV-2 during their hospitalisation, and were treated with remdesivir or dexamethasone (used within Providence exclusively for patients who require supplemental oxygen) during hospitalisation.

Vaccination data were obtained from electronic medical records and included vaccines administered by the health-care system, patient-reported vaccinations, and integrated data from comprehensive state vaccination registries. Full vaccination date was defined as 14 days after the final vaccination in a recognised series (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], or Ad26.COV2 [Janssen]), and time since vaccination was defined as the number of days between the most recent vaccine dose and the index admission date. We also captured vaccination type. We excluded patients who had received more than one type of vaccine, or who had been partly vaccinated. We also excluded patients who had received booster vaccinations before their index encounter. Patients were flagged if they had a previous COVID-19 diagnosis (ICD-10 codes U07.1 or Z86.16) or positive nucleic acid amplification test 50 days or more before the index admission. Severe breakthrough infections were defined as a severe SARS-CoV-2 infection for any patient with full vaccination status.

Comorbidities for each patient were identified via ICD-10 clinical modification billing diagnosis codes from the index encounter and the 365 days preceding the encounter. Codes were grouped into Agency for Healthcare Research and Quality Clinical Classifications Software-Refined categories for analysis. Other patient-level variables were age at admission, race, sex, date of admission, body-mass index, and smoking status.

We did not have individual sequencing data for each COVID-19 case in our study, so we used the US Centers for Disease Control and Prevention (CDC) weekly estimates of delta prevalence across United States Department of Health and Human Services regions as a proxy for the effect of delta on outcomes. For each geographical region in our analysis, the daily prevalence of delta at the time of each admission was linearly interpolated from the weekly CDC summary as a weighted average of the midpoint of the adjacent weeks. We then flagged all admissions that occurred during periods of high delta prevalence within their relevant geography (defined as 75% or more of all reported cases in the region).

Case-control design
We applied a case-control design, with patients admitted to the hospital for severe COVID-19 constituting cases, and a 4:1 matched group of patients admitted within 5 days and at the same hospital for any other non-elective reason constituting controls. Similar designs have been used to estimate vaccine effectiveness in previous studies.

Similar case-control studies have used different approaches to identify severe COVID-19 cases or matched controls. We preferred our approach because it allowed for a better match on date and site of care, which is important for separating out the effect of time since vaccination and delta variant prevalence. However, as a sensitivity analysis, we replicated our analyses using several alternative specifications with different methods of defining severe COVID-19 admissions, vaccination status, and matching to control cases, with results available in the appendix (pp 8–19).

Approach for calculating vaccine effectiveness
Vaccine effectiveness was calculated for any given subgroup as follows:

\[ VE_g = 1 - \frac{d_g}{c_g} \]

where \( a_g \) is the count of COVID-19 admissions with full vaccination, \( b_g \) is the count of non-COVID-19 admissions with full vaccination, \( c_g \) is the count of COVID-19 admissions with no vaccination, and \( d_g \) is the count of non-COVID-19 admissions with no vaccination. Vaccine effectiveness is equal to 1 minus the odds ratio (OR), which we used instead of rate ratios because they are scale independent, which helps reduce bias during virus surges.
Case-control logistic regression analysis
We used multivariable conditional logistic regression analysis to identify factors associated with severe breakthrough infection risk. Our equation took the stylised form:

$$P(Y_{ij} = 1, Y_{i,j} = 0 \text{ for } 2 \leq j \leq 5 | X_{i,1}, \ldots, X_{i,5}) = \frac{e^{\beta_{vax} X_{i,1} + \sum_{j=2}^{5} \beta_{vax}^{j} X_{i,j}}}{e^{\beta_{vax} X_{i,1} + \sum_{j=2}^{5} \beta_{vax}^{j} X_{i,j}} + e^{\sum_{j=1}^{5} \beta_{vax}^{j} X_{i,j} + \sum_{j=1}^{5} \beta_{vax}^{j} X_{i,j}}}$$

where $i$ indexes a set of patients and $j$ indexes an individual within the set, $Y_i$ indexes the outcome of severe COVID-19 admission for an individual, and $X_i$ indexes the values of the covariates for that individual. $\beta_{vax}$ is the coefficient for the OR of vaccination, $\beta_{vax}$ is the coefficient matrix for the variables interacting with vaccination status and thus represents the effects of those variables on vaccine effectiveness, and $\beta_{vax}$ is the

### Table 1: Characteristics of cases and controls

| Cases (n=9667) | Matched controls (n=38668) |
|---------------|---------------------------|
| **Age, years** |                           |
| Mean (SD)     | 57.5 (16.6)               | 61.6 (19.6)               |
| 70–79         | 1490 (15.4 %)             | 7775 (20.1 %)             |
| ≥80           | 964 (10.0%)               | 7629 (19.7 %)             |
| **Sex**       |                           |
| Female        | 4121 (42.6%)              | 20127 (52.1%)             |
| Male          | 5546 (57.4%)              | 18541 (47.9%)             |
| **Race or ethnicity** |                     |
| White         | 6280 (65.0%)              | 27730 (71.7%)             |
| Latino or Latina | 1631 (16.9%)          | 4579 (11.8%)              |
| Black         | 372 (3.8%)                | 1652 (4.3%)               |
| Asian         | 334 (3.5%)                | 1643 (4.2%)               |
| Other         | 1050 (10.9%)              | 3064 (7.9%)               |
| **Vaccination and COVID-19 status** |         |
| Vaccinated    | 1293 (13.4%)              | 22308 (57.7%)             |
| mRNA-1273 (Moderna) | 370 (3.8%)          | 10119 (26.2%)             |
| Ad26.COV2 (Janssen) | 279 (2.9%)          | 2018 (5.2%)               |
| BNT162b2 (Pfizer-BioNTech) | 634 (6.6%) | 9882 (25.6%)              |
| Previously had COVID-19 | 53 (0.5%)         | 1491 (3.9%)               |
| Days since last vaccination | 162 (118–198) | 141 (92–178)              |

Data are n (%) or median (IQR), unless otherwise indicated. Data are from Providence Electronic Medical Records on inpatient hospital encounters for individuals aged ≥18 years on April 1–Oct 26, 2021. Data comprise 9667 cases and 38 668 controls. Red lines represent mean vaccine effectiveness averages based on a rolling 30-day window for encounter data and a rolling 10-year window for patient age. The shaded areas represent 95% CIs.

Figure 1: Vaccine effectiveness against severe COVID-19 by encounter date (A) and patient age (B)
coefficient matrix for the variables not interacting with vaccination and is interpreted as adjusting the odds of admission to hospital with severe COVID-19. Under this approach, each covariate (eg, asthma) is assessed both in terms of its direct effect on the outcome (probability of a severe COVID-19 admission) and its interaction with vaccine status (modifying the effect of vaccine status on probability of severe COVID-19 admission). The latter terms are our primary variables of interest in this paper. Once the model was fit, we isolated the interaction coefficients to calculate estimates of vaccine effectiveness conditional on any given set of covariate values.

Generating CIs for vaccine effectiveness estimates
We used bootstrapping to produce 95% CIs around our vaccine effectiveness estimates. Under this approach, we created multiple (n=1000) distinct samples from our single set of observations and used the resampling distribution to construct a 95% CI around our mean effect estimates.

Role of the funding source
There was no funding source for this study.

Results
Between April 1, 2021, Oct 26, 2021, we observed 9667 admissions for severe COVID-19 (ie, cases). Overall, 1293 (13·4%) of 9667 cases were fully vaccinated at the time of admission, compared with 22308 (57·7%) of 38668 controls. The median time between vaccination and hospital admission among cases was 162 days (IQR 118–198). Table 1 shows the composition of our sample, including cases (hospital admissions for severe COVID-19) and controls (hospital admissions for any other reason, matched by date and hospital in a 4:1 ratio to cases).

Overall vaccine effectiveness declined mostly over the course of the summer, from 94·5% (95% CI 91·4–96·5) in April, 2021 (pre-delta), to 84·0% (81·6–86·1) by October, 2021 (figure 1). Vaccine effectiveness was above 90% for all ages younger than 70 years, but as low as 72% (95% CI 62·3–79·2) for those aged 90 years and older.

Similar to previous studies, we found that protection peaks about 50 days after completing vaccination and begins to wane slightly after about 100 days (figure 2A). Notably, we observed evidence of an accelerated decline in protection after 200 days, with overall vaccine effectiveness falling from 94·0% (95% CI 92·8–95·0) in days 50–100 to 80·4% (77·8–82·7) in days 200–250. We observed evidence of continued decline after 250 days, albeit with wider CIs because of fewer observations in this range. We found that across age groups and delta prevalence levels, protection against delta was uniformly lower across all time periods, but that attenuation of protection over time remained evident, especially in older patients (figure 2B). We observed especially stark reductions for those aged 80 years and older after 200 days since vaccination, with vaccine effectiveness falling to 78·4% (95% CI 73·6–82·4) 200–250 days after vaccination for this age group.

Overall, the mRNA-1273 (Moderna) vaccine showed the highest overall vaccine effectiveness across our study period, starting at 97·3% (95% CI 96·0–98·2) in days 50–100 after vaccination, then falling to 87·6% (84·5–90·1) by days 200–250, an overall decline of 9·7 percentage points (figure 3). The vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) began similarly to mRNA-1273 at 94·9% (93·2–96·2), but showed substantially greater attenuation, falling to 74·1% (69·6–77·9) by 200–250 days, a decline of 20·8 percentage points. Finally, the Ad26.COVID vaccine offered lower initial protection...
Articles

(78.5% at days 50–100, 95% CI 71.3–83.9) but showed less substantial attenuation over time, remaining at 72.6% (53.7–83.8) by days 200–250, a decline of 5.9 percentage points.

When considering adjusted ORs from our case-control regression analysis, differences by vaccine type remain apparent (Table 2). Relative to those who received the mRNA-1273 (Moderna) vaccine and holding other factors constant, patients who received the Ad26.COV2 (Janssen) vaccine had substantially higher relative odds of hospitalisation for severe COVID-19 (adjusted OR 14.53, 95% CI 8.43–25.03). Patients who received the BNT162b2 (Pfizer-BioNTech) vaccine also had somewhat higher relative odds or hospitalisation, although the difference was not significant (1.39, 0.98–1.97). Time since vaccination also mattered. After peak protection at day 56 (8 weeks) after vaccine course completion, each subsequent week saw the relative odds of a severe breakthrough infection increase by around 5% (adjusted OR 1.05, 95% CI 1.03–1.07). Results also suggest that the delta variant is available in the appendix (pp 23–24). OR=odds ratio. *Reference is week 8 after vaccination completion, which is the point of peak protection. †For comorbidities, interaction terms of each relevant factor with vaccine status—that is, the adjusted formula provided in the Methods. Displayed adjusted ORs represent the

### Table 2: Logistic regression analysis to identify factors associated with severe breakthrough COVID-19 infections in fully vaccinated individuals

| Factor                      | Adjusted OR (95% CI) | p value |
|------------------------------|----------------------|---------|
| Age, years                   |                      |         |
| 70–79 (vs <70 reference)    | 1.11 (0.93–1.33)     | 0.26    |
| ≥80 (vs <70 reference)      | 1.76 (1.43–2.15)     | <0.0001 |
| Male (vs female referent)   | 1.03 (0.90–1.18)     | 0.69    |
| Race or ethnicity            |                      |         |
| Black (vs White reference)  | 1.39 (0.97–1.99)     | 0.075   |
| Latino or Latina (vs White reference) | 1.10 (0.89–1.34) | 0.38    |
| Asian (vs White reference)  | 0.82 (0.59–1.13)     | 0.22    |
| Other (vs White reference)  | 1.09 (0.86–1.39)     | 0.46    |
| Vaccination status           |                      |         |
| BNT162b2 (Pfizer-BioNTech; vaccination with mRNA-1273 [Moderna] as reference) | 1.39 (0.98–1.97) | 0.067 |
| Ad26.COV2 (Janssen; vaccination with mRNA-1273 [Moderna] as reference) | 14.53 (8.43–25.03) | <0.0001 |
| Vaccine timing               |                      |         |
| Weeks before full protection at week 8 | 1.29 (1.16–1.44) | <0.0001 |
| Weeks after full protection at week 8 | 1.05 (1.03–1.07) | <0.0001 |
| Comorbidities†               |                      |         |
| Alcohol or drug dependency   | 1.81 (1.47–2.23)     | <0.0001 |
| Asthma                       | 0.95 (0.78–1.16)     | 0.62    |
| Cancer                       | 1.93 (1.60–2.33)     | <0.0001 |
| Chronic kidney disease       | 1.41 (1.19–1.67)     | 0.0010  |
| Chronic obstructive pulmonary disease | 1.03 (0.86–1.23) | 0.27    |
| Cognitive disease            | 1.25 (0.99–1.57)     | 0.059   |
| Coronary artery disease      | 1.05 (0.89–1.24)     | 0.53    |
| Diabetes                     | 1.12 (0.97–1.30)     | 0.11    |
| Heart failure                | 1.47 (1.24–1.75)     | <0.0001 |
| Hypertension                 | 1.43 (1.20–1.71)     | 0.0018  |
| Immunodeficiency             | 1.49 (1.13–1.96)     | 0.0052  |
| Obesity (body-mass index ≥35 kg/m²) | 0.82 (0.69–0.96) | 0.016   |
| Rheumatological disease      | 1.52 (1.16–2.01)     | 0.0027  |
| Smoker (current)             | 1.30 (0.96–1.77)     | 0.091   |
| Organ transplantation        | 3.44 (2.12–5.57)     | <0.0001 |
| All delta (vs no delta reference) | 2.00 (1.35–2.95) | 0.0002  |

All data are from Providence Electronic Medical Records on inpatient hospital encounters for people aged ≥18 years on April 1 to Oct 26, 2021 (n=9667 cases, 38 668 controls). Output produced via multivariable logistic regression using the www.thelancet.com/respiratory Vol 10 June 2022
were found not to be. Age was also a key predictor of risk, with patients aged 80 years and older having substantially higher relative odds of severe breakthrough infection than those younger than 70 years (1.76, 1.43–2.15). We found no evidence of differential risk by race or sex in our primary analysis.

Discussion
In this study, we used comprehensive hospital admission data to analyse the risk of severe COVID-19 in previously vaccinated individuals, with the goal of understanding differences in waning protection by vaccine type and identifying the key risk factors for severe breakthrough infections to inform the targeting of potential vaccine booster programmes. Consistent with other studies, we found that vaccine effectiveness against hospitalisation began to decline after 6 months, especially for older patients. Unlike most other studies, our data were able to stretch beyond 6 months, after which we found evidence of rapidly waning protection, especially for patients aged 80 years or older. We were able to identify important differences by vaccine type and patient characteristics that could help inform potential booster programmes.

Overall, we found that vaccines were less effective against severe COVID-19 by October, 2021, compared with April, 2021. Vaccine effectiveness was steady up to June, 2021, then began to decline in July, 2021, as delta prevalence increased and many patients became further removed from their vaccination dates.

The median time since full vaccination among cases in our study was about 5 months (162 days). Most patients had only modest declines in protection over the first 6 months since their final dose. However, we found evidence of accelerated decline after 200 days.

All vaccines showed evidence of strong continuing protection against hospitalisation, but there were differences in how their protection changed over time. Patients who received mRNA-1273 (Moderna) had the highest overall protection and saw relatively modest attenuation over time. By contrast, patients who received the BNT162b2 (Pfizer-BioNTech) vaccine began with similar levels of protection, but this protection diminished more substantially over time. The AdZ6. COV2 (Janssen) vaccine offered less initial protection, but vaccine effectiveness remained mostly steady over time. Our Janssen estimates were based on fewer observations and had wider 95% CIs than did those for the Pfizer-BioNTech and Moderna vaccines, so should be interpreted with caution.

Attenuating vaccine protection over time is related to age. Overall, vaccine effectiveness remained at or above 90% until age 70, after which we observed increasing declines in effectiveness with age. Importantly, all age groups had only modest loss of protection against hospitalisation over the first 200 days after vaccination, but after 200 days we observed evidence of eroded protection, especially among those aged 70 years and older. We found a particularly sharp drop in vaccine effectiveness for patients aged 80 years and older after 200 days since vaccination. Even without this age difference, vaccine effectiveness declines in general are more dangerous for older patients; a decline in protection for patients aged 80 years and older will probably lead to many more hospitalisations and deaths compared with a similar decline in younger people, given that older age had been associated with more severe COVID-19 outcomes. Overall our findings suggest an urgent need for booster shots among older people who are 200 days or more from their initial vaccination date.

As expected, disorders associated with immunocompromise increased the risk of severe breakthrough infections, including cancer, chronic kidney disease, and organ transplantation. Less easily explained is the association of certain other chronic diseases with lower vaccine effectiveness, such as hypertension and heart failure, but not others, such as diabetes, coronary artery disease, or obesity. Further research might be needed to explore the mechanisms of interaction between chronic diseases and vaccine protection. Overall, our results suggest that patients with immune compromising disorders, hypertension, and heart failure could be the highest priority for targeted booster vaccination campaigns.

Overall, our data show strong protection against hospitalisation over the first 6 months after vaccination for most people, but evidence of waning protection after 200 days, particularly for patients aged 70 years and older. We found evidence that vaccine effectiveness is lower for patients with immune compromising conditions, hypertension, or heart failure. Finally, our data suggest that the mRNA-1273 (Moderna) vaccine offers the strongest and most robust protection over time. A series of sensitivity analyses (appendix pp 8–18) testing alternative specifications and matching strategies largely supported our overall findings.

Our findings can be contextualised against several other real-world studies of vaccine effectiveness. A large study of Swedish registries found an even stronger decline in vaccine effectiveness against hospitalisation after 180 days, albeit with a different mix of vaccine types, and a systematic review found that on average across the literature, vaccine effectiveness against severe disease decreased by 9.7 percentage points (95% CI 5.9–14.7) over the first 6 months after vaccination, roughly in line with our estimate of 7.5 percentage points by days 150–200. An Italian health ministry report found less evidence for declining vaccine effectiveness at 6 months, but noted the beginnings of potential decline in the face of increasing delta variant cases at the end of their follow-up period. Furthermore, several studies have found similar evidence for age and comorbidities as key drivers of risk for breakthrough infections or severe breakthrough infections.

Our study has several key limitations. First, our data are regionally concentrated and might not be nationally
representative of all COVID-19 admissions and do not include results for children younger than 18 years. We also lacked individual sequencing data for infections, and thus relied on a proxy (regional prevalence) to estimate the influence of the delta variant on outcomes. We were only able to examine vaccine effectiveness against severe disease, but infections that do not result in a hospital admission might still have serious health consequences. Like other observational vaccine effectiveness studies, our analysis assumed a similar risk of exposure to COVID-19 for vaccinated and unvaccinated people, and we were unable to assess other factors, such as masking, distancing, or other social mitigation strategies that might themselves be associated with vaccine uptake.

In conclusion, this study of large-scale hospitalisation data in a major US health-care system suggests that vaccines remain highly effective against severe COVID-19, even in the age of the delta variant. However, we found evidence of waning protection after 200 days, especially in those older than 80 years or with certain clinical comorbidities. Additional protection (eg, a booster vaccination) might be warranted for everyone, but especially for these populations. In addition to promoting general vaccine uptake, clinicians and policy makers should consider prioritising booster vaccinations in those most at risk of severe COVID-19.

Contributors
BJW contributed to the overall design, literature search, data interpretation, and manuscript writing. ST contributed to data curation and collection, methodology, analysis, data visualisation, and data interpretation. GAD contributed to overall study design, literature search, data interpretation, and manuscript writing. TF contributed to data interpretation. GTP contributed to data curation and collection, methodology, analysis, and data interpretation. AR contributed to overall study design, data curation and collection, analysis, interpretation, manuscript writing, and supervision. ST, GTP, TF, and AR have accessed and can verify the underlying data. AR was responsible for the decision to submit the manuscript, and all authors have reviewed and approved the final manuscript text. All authors had full access to all the data in the study.

Declaration of interests
We declare no competing interests.

Data sharing
Upon request, beginning 6 months after publication and ending 5 years after publication, the authors will share fully de-identified individual participant data that underlie the results reported in this Article upon request for additional analysis of vaccine effectiveness. Data will be considered for sharing with investigators whose use of the data has been approved by an independent institutional review board. The corresponding author should be contacted for access.

References
1 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603–15.
2 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 401–16.
3 Young-Xu Y, Kovacs C, Roberts J, et al. Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans. JAMA Netw Open 2021; 4: e2128391.
4 Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385: 1761–73.
5 Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385: 985–94.
6 Pouwels KB, Pritchard E, Matthews PC, et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021; 27: 2117–35.
7 Shekhi A, McMenamin J, Taylor B, Robinson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021; 397: 2461–62.
8 Israel Ministry of Health. Decline in vaccine effectiveness against infection and symptomatic illness. July 5, 2021. https://www.gov.il/en/departments/news/50071903 (accessed Aug 29, 2021).
9 Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings—Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1059–62.
10 Keelner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 2021; 385: 1330–32.
11 Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021; 27: 2117–35.
12 Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March–July 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1156–62.
13 Nanduri S, Pulshviti T, Derazo G, et al. Effectiveness of Pfizer BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant—National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1156–59.
14 Rosenberg ES, Holtgrave DR, Dorahwila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1156–59.
15 Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398: 1407–16.
16 Chernaitytli H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021; 385: e83.
17 Israel Ministry of Health. Third dose of the COVID-19 vaccine—now also for everyone 30 years of age and older. Aug 24, 2021. https://www.gov.il/en/departments/news/24082021-01 (accessed Aug 29, 2021).
18 US Centers for Disease Control and Prevention. Considerations for COVID-19 vaccination in moderately or severely immunocompromised people. https://www.cdc.gov/vaccines/clinical-considerations/immunocompromised.html (accessed Aug 30, 2021).
19 US Centers for Disease Control and Prevention. Joint statement from HHS Public Health and medical experts on COVID-19 booster shots. Aug 18, 2021. https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html (accessed Aug 30, 2021).
20 WHO. Interim statement on COVID-19 vaccine booster doses. Aug 10, 2021. https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses (accessed Aug 29, 2021).
21 Bhimraj A, Morgan RL, Shurmaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Version 5.1.2. 2021. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed Sept 15, 2021).
22 Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1337–43.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–49.

Agency for Healthcare Research and Quality. Clinical classifications software refined (CCSR) for ICD-10-CM diagnoses. https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/dxccsr.jsp (accessed Dec 15, 2021).

US Centres for Disease Control and Prevention. CDC Data Tracker. https://covid.cdc.gov/covid-data-tracker/#variant propor-tions (accessed Nov 17, 2021).

Evans SJW, Jewell NP. Vaccine effectiveness studies in the field. N Engl J Med 2021; 385: 650–51.

Grannis SJ, Rowley EA, Ong TC, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (delta) variant predominance—nine states, June–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1291–93.

Husain SA, Tsapepas D, Paget KF, et al. Postvaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplant recipients. Kidney Int Rep 2021; 6: 1699–700.

Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transplant Infect Dis 2021; 23: e13705.

Rincon-Arevala H, Choi M, Stefanski A, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 2021; 6: ealj031021.

Nordström P, Ballin M, Nordström A. Effectiveness of COVID-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. SSRN 2021; published online Oct 25. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949430 (preprint).

Feikin D, Higden MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. SSRN 2021; published online Nov 18. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3961378 (preprint).

Pezzotti P, Fabbiani M, Filia A, et al. Impact of COVID-19 vaccination on the risk of SARS-CoV-2 infection and hospitalization and death in Italy. Sept 30, 2021. https://www.iss.it/documents/20126/0/Report+on+vaccine+effectiveness+Italy+fourth+report.pdf (accessed Dec 22, 2021).

Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ 2021; 374: n2244.

Grange Z, Buelo A, Sullivan C, et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. Lancet 2021; 398: 1799–800.